Imugene Ltd
IMU
Company Profile
Business description
Imugene Ltd is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumours. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.
Contact
4-6 Bligh Street
Suite 12.01, Level 12
SydneyNSW2000
AUST: +61 294230881
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
5
Stocks News & Analysis
stocks
Avoid these overvalued ASX shares
The two shares with the highest price to fair value in our Australian coverage.
stocks
Going into earnings, is Microsoft stock a buy, a sell, or fairly valued?
Watching AI monetization, capex’s impact on margins, and guidance on Azure.
stocks
Lithium’s latest drop and what it means for ASX investors
Volatility returns to the lithium market.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,995.70 | 5.50 | 0.06% |
| CAC 40 | 8,363.14 | 23.03 | 0.28% |
| DAX 40 | 25,011.35 | 164.66 | 0.66% |
| Dow JONES (US) | 52,224.64 | 385.38 | 0.74% |
| FTSE 100 | 10,585.91 | 61.15 | 0.58% |
| HKSE | 24,950.60 | 181.69 | -0.72% |
| NASDAQ | 25,837.21 | 329.13 | 1.29% |
| Nikkei 225 | 67,436.77 | 1,204.59 | 1.82% |
| NZX 50 Index | 13,691.46 | 35.43 | 0.26% |
| S&P 500 | 7,509.20 | 65.92 | 0.89% |
| S&P/ASX 200 | 8,811.20 | 4.70 | 0.05% |
| SSE Composite Index | 3,877.52 | 13.15 | 0.34% |